About Detlev Biniszkiewicz
Detlev Biniszkiewicz is a chairman of the board at NextPoint Therapeutics.
Detlev Biniszkiewicz reports to the SEC as a director of 1 public company: iTeos Therapeutics (ITOS).
Detlev Biniszkiewicz first appears on SEC filings in 2020.
Experience
This experience comes from Detlev Biniszkiewicz's profile and from SEC filings. For roles taken from filings, the years are when the filings name Detlev Biniszkiewicz in the role, so the role may have started earlier or lasted longer.
NextPoint Therapeutics, Inc. Current
Founder, Chairman of the Board
2018 – Present · Cambridge, MA
Develops targeted cancer treatments for patients with solid tumors.
MB
MPM BioImpact Current
Managing Director/Investment Partner - MPM Innovation Fund
2018 – Present
MB
Montis Biosciences
Board of Directors - Independent
2019 – 2024
II
iTeos Therapeutics, Inc.
Board of Directors
2019 – 2023 · Public company (ITOS)
1O
1K Oncology
Founder/CEO
2020 – 2022
MT
Maverick Therapeutics
Board of Directors
2018 – 2021
TT
Tilos Therapeutics
Board of Directors - Independent
2018 – 2020
SI
Surface Oncology Inc.
Board Of Directors
2015 – 2018
AS
AstraZeneca
Vice President, Oncology - Strategy, External Science & Licensing
2011 – 2015
NO
Novartis
Global Head - Portfolio Management & Analysis
2007 – 2011
BG
Boston Consulting Group
Principal
2001 – 2007
Key Colleagues at Startups
The people Detlev Biniszkiewicz works with at each company, as listed on that company's latest Form D.
NextPoint Therapeutics, Inc. · Form D, Jul 30, 2026
Paulina Hill
Board Member
Ivan Cheung
Chief Executive Officer and director
R. Jacob Vogelstein
Board Member
JL
Jeffrey Lacey
Secretary & Treasurer
Brian Shuster
Board Member
Rakhshita Dhar
Board Member
Axel Hoos
Board Member